SUMMARY
Aaron S. Mansfield, M.D., is a medical oncologist whose focus is on thoracic malignancies and early therapeutics. He has played a significant role, including principal investigator, in clinical trials leading to the Food and Drug Administration's approval of agents for treating thoracic malignancies. These medicines include atezolizumab for small cell lung cancer, pralsetinib for rearranged during transfection fusion-positive non-small cell lung cancer, and the combination of ipilimumab and nivolumab for mesothelioma.
Dr. Mansfield explores translational projects to discover and validate biomarkers in thoracic malignancies. He has received funding from multiple peer-reviewed organizations, including the National Cancer Institute, the Department of Defense and the Mark Foundation for Cancer Research.
Focus areas
- Immunotherapy biomarkers. Dr. Mansfield and his colleagues identified a signature that predicts which people with mesothelioma are most likely to benefit from treatment with immunotherapy. This signature is being studied in other tumor types. He also is working on developing blood-based biomarkers.
- Drug development. Dr. Mansfield is the principal investigator of multiple cooperative group clinical trials, including the ROS1-crizotinib arm of the National Cancer Institute-sponsored Molecular Analysis for Therapy Choice clinical trial and others for pleural and peritoneal mesothelioma. He collaborates with many pharmaceutical companies researching new therapies for people with pleural and peritoneal mesothelioma.
Significance to patient care
Dr. Mansfield hopes to introduce new treatments for lung cancer, mesothelioma and rare tumors. He is a principal investigator on many clinical trials that are available to people with these conditions.
Professional highlights
- Journal of Thoracic Oncology:
- Top reviewer, 2016-present.
- Letter of recognition for reviewing 22 manuscripts, 2016.
- Collaborative Cancer Research Program award, Mayo Clinic Comprehensive Cancer Center and Cancer Research Karolinska Institutet, 2024.
- Co-director, Precision Cancer Therapeutics Program, Mayo Clinic Center for Individualized Medicine, Mayo Clinic, 2020-2023.
- Patient Experience Provider Recognition Award, Mayo Clinic, 2020.
- American Society of Clinical Oncology:
- Travel Award, 2013.
- Merit Award, 2012.
- Tow Shung Tan Humanism in Medicine Award, Mayo Clinic, 2013.